Home News About Us Contact Contributors Disclaimer Privacy Policy Help FAQ

Home
Search
Quick Search
Advanced
Fulltext
Browse
Collections
Persons
My eDoc
Session History
Login
Name:
Password:
Documentation
Help
Support Wiki
Direct access to
document ID:


          Institute: MPI für molekulare Genetik     Collection: Department of Computational Molecular Biology     Display Documents



  history
ID: 265199.0, MPI für molekulare Genetik / Department of Computational Molecular Biology
Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival
Authors:Kristiansen, Glen; Pilarsky, Christian; Wissmann, Christoph; Kaiser, Simone; Bruemmendorf, Thomas; Roepcke, Stefan; Dahl, Edgar; Hinzmann, Bernd; Specht, Thomas; Pervan, Janja; Stephan, Carsten; Loening, Stefan; Dietel, Manfred; Rosenthal, André
Language:English
Date of Publication (YYYY-MM-DD):2005-02-01
Title of Journal:The Journal of Pathology
Journal Abbrev.:J Path
Volume:205
Issue / Number:3
Start Page:359
End Page:376
Copyright:© 1999-2006 John Wiley & Sons, Inc. All Rights Reserved.
Review Status:not specified
Audience:Experts Only
Abstract / Description:In order to screen for differentially expressed genes that might be useful in diagnosis or therapy of prostate cancer we have used a custom made Affymetrix GeneChip containing 3950 cDNA fragments. Expression profiles were obtained from 42 matched pairs of mRNAs isolated from microdissected malignant and benign prostate tissues. Applying three different bioinformatic approaches to define differential gene expression, we found 277 differentially expressed genes, of which 98 were identified by all three methods. Fourteen per cent of these genes were not found in other expression studies, which were based on bulk tissue. Resultant candidate genes were further validated by quantitative RT-PCR, mRNA in situ hybridization and immunohistochemistry. AGR2 was over-expressed in 89% of prostate carcinomas, but did not have prognostic significance. Immunohistologically detected over-expression of MEMD and CD24 was identified in 86% and 38.5% of prostate carcinomas respectively, and both were predictive of PSA relapse. Combined marker analysis using MEMD and CD24 expression proved to be an independent prognostic factor (RR = 4.7, p = 0.006) in a Cox regression model, and was also superior to conventional markers. This combination of molecular markers thus appears to allow improved prediction of patient prognosis, but should be validated in larger studies. Copyright © 2004 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Free Keywords:prostate cancer
tumour profiling
microarray hybridization
immunohistochemistry
CD166
CD24
External Publication Status:published
Document Type:Article
Communicated by:Martin Vingron
Affiliations:MPI für molekulare Genetik
External Affiliations:Institute of Pathology, Charité University Hospital, Berlin, Germany;
metaGen Pharmaceuticals, Berlin, Germany;
Department of Surgery, University Hospital Carl Gustav Carus, Dresden, Germany;
Department of Gastroenterology and Hepatology, Charité University Hospital, Berlin, Germany;
Institute of Pathology, RWTH, Aachen, Germany;
Department of Urology, Charité University Hospital, Berlin, Germany;
Signature Diagnostics AG, Berlin, Germany.
Identifiers:DOI:10.1002/path.1676
ISSN:0022-3417
Full Text:
Sorry, no privileges
The scope and number of records on eDoc is subject to the collection policies defined by each institute - see "info" button in the collection browse view.